EGFR and non-small cell lung carcinoma: In our cohort, there was almost a six-fold increased incidence (18% vs. 3%) of diffuse lung metastases in patients with metastatic EGFR-mutant NSCLC compared to patients with EGFR-wild type NSCLC.